SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Income from Continuing Operations came in at 46506680.0 in Q1 2026, down 323.92% YoY from 20769623.9 in Q1 2025, and down 207.34% on a QoQ basis from 15131823.0 in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Income from Continuing Operations data on file, last reported at 46506680.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 323.92% year-over-year to 46506680.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84838038.0 (down 121.91% YoY) and the FY2025 annual result came in at 73590831.0, down 71.9% from the prior year.
- Income from Continuing Operations slipped to 46506680.0 in Q1 2026, from 15131823.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 985863.0 in Q1 2022 to a low of 46506680.0 in Q1 2026.
- A 5-year average of 11117807.65 and a median of 7848966.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 845.93% — and 2024, when it jumped 58.11%.
- Tracing SABS's Income from Continuing Operations over 5 years: stood at 7848966.0 in 2022, then slumped by 191.21% to 22856763.0 in 2023, then jumped by 58.11% to 9574420.0 in 2024, then sank by 58.04% to 15131823.0 in 2025, then plunged by 207.34% to 46506680.0 in 2026.
- The last three Income from Continuing Operations figures came in at 46506680.0 (Q1 2026), 15131823.0 (Q4 2025), and 12752386.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | SAB Biotherapeutics | 296.28 Mn | 296.28 Mn | - | -21.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.73 Mn |
| Mar 31, 2026 | -19.01 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -12.07 Mn |
| Jun 30, 2025 | -9.78 Mn |
| Mar 31, 2025 | -10.78 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |